Kinetic nomograms assist individualization of drug regimens

Clinical Pharmacokinetics

Volumn 50, Issue 12, 2011, Pages 773-779

  Marouani, Hafedh ^a   Zografidis, Anastasios ^b   Iliadis, Athanassios ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Dose prediction; Drug monitoring; Pharmacokinetic modelling; Pharmacokinetics; Sirolimus

Indexed keywords

RAPAMYCIN;

ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CLINICAL PROTOCOL; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; KINETIC NOMOGRAM; NOMOGRAM; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SIMULATION; STEADY STATE;

BAYES THEOREM; COMPUTER SIMULATION; DRUG MONITORING; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; NOMOGRAMS; SIROLIMUS;

EID: 81255189048     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11594000-000000000-00000     Document Type: Article

References (33)

1. Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med 2009; 24 (1): 1-10
2. Spector R, Park GD, Johnson GF, et al. Therapeutic drug monitoring. Clin Pharmacol Ther 1988; 43: 345-53
3. Alnaim L. Therapeutic drug monitoring of cancer chemotherapy. J Oncol Pharm Pract 2007; 13 (4): 207-21
4. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002; 16 (4): 253-62 (Pubitemid 35205335)
5. Rousseau A, Leger F, LeMeur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit 2004; 26 (1): 23-30 (Pubitemid 38140906)
6. Eldesoky E,Meinshausen J, Bü hl K, et al. Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs pharmacokinetic studies. Ther Drug Monit 1993; 15 (4): 281-8 (Pubitemid 23237578)
7. Steimer JL, Vozeh S, Racine-Poon A, et al. The population approach: rationale, methods, applications in clinical pharmacology and drug development. In: Welling PG, Balant LP, editors. Pharmacokinetics of drugs, handbook of experimental pharmacology. Berlin: Springer-Verlag, 1994: 405-51
8. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22 (6): 447-67
9. Birkett DJ. Therapeutic drug monitoring. Australian Prescriber 1997; 20: 9-11 (Pubitemid 27112517)
10. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52 (Suppl. 1): 5-10
11. Musuamba FT, Rousseau A, Bosmans JL, et al. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet 2009; 48 (11): 745-58
12. Kawamata S, Sakaida H, Hori T, et al. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 1998; 91 (2): 561-9 (Pubitemid 28053379)
13. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24 (3): 330-50 (Pubitemid 34275858)
14. Holt DW, Denny K, Lee TD, et al. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant Proc 2003; 35 (3 Suppl.): 157-61
15. Oellerich M, Armstrong VW, Streit F, et al. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin Biochem 2004; 37 (6): 424-8 (Pubitemid 38746635)
16. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005; 28 (2): 153-81 (Pubitemid 40321770)
17. Aspeslet LJ, Yatscoff RW. Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation. Clin Ther 2000; 22 (Suppl. B): 86-92
18. Meier-Kriesche HU, Kaplan B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin Ther 2000; 22 (Suppl. B): 93-100
19. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS J 2004; 6 (4): e28
20. Cattaneo D, Merlini S, Pellegrino M, et al. Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 2004; 4 (8): 1345-51 (Pubitemid 39013583)
21. Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin Pharmacokinet 2006; 45 (11): 1135-48 (Pubitemid 44631392)
22. Iliadis A, Bruno R, Cano JP. Steady-state dosage regimen calculations in linear pharmacokinetics. Int J Biomed Comput 1986; 18: 167-82 (Pubitemid 16076517)
23. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357 (25): 2562-75 (Pubitemid 350294223)
24. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74 (8): 1070-6 (Pubitemid 35216097)
25. Watson CJE, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5 (10): 2496-503
26. Iliadis A, Brown AC, Huggins ML. APIS: a software for identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Methods Programs Biomed 1992; 38 (4): 227-39 (Pubitemid 23003747)
27. MathWorks Inc. Matlab: high-performance numeric computation and visualization software (version 7.0). Natick (MA): MathWorks Inc., 2004
28. Silverman BW. Density estimation for statistics and data analysis. London: Chapman and Hall, 1992
29. Evans WE, Schentag JJ, Jusko WJ. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver (WA): Applied Therapeutics; 1992
30. KahanBD, Napoli KL,KellyPA, et al.Therapeutic drugmonitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14 (2): 97-109 (Pubitemid 30171208)
31. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001; 28 (8): 743-51 (Pubitemid 33089217)
32. Stanford BL, Shah SR, Ballard EE, et al. A randomized trial assessing the utility of a test-dose program with taxanes. CurrMed Res Opin 2005; 21 (10): 1611-6 (Pubitemid 41505027)
33. Ferron GM, Mishina EV, Zimmerman JJ, et al. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther 1997; 61 (4): 429-41